ARS Operating Cycle from 2010 to 2026

SPRY Stock   10.21  0.36  3.41%   
ARS Pharmaceuticals Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle will likely drop to 111.20 in 2026. During the period from 2010 to 2026, ARS Pharmaceuticals Operating Cycle regression line of annual values had r-squared of  0.12 and arithmetic mean of  1,164. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
117.05
Current Value
111.2
Quarterly Volatility
3.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ARS Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ARS Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 67.5 K, Gross Profit of 82.8 M or Other Operating Expenses of 111.4 M, as well as many indicators such as Price To Sales Ratio of 9.81, Dividend Yield of 0.0 or PTB Ratio of 3.76. ARS financial statements analysis is a perfect complement when working with ARS Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with ARS Stock
Check out the analysis of ARS Pharmaceuticals Correlation against competitors.
For more information on how to buy ARS Stock please use our How to Invest in ARS Pharmaceuticals guide.

Latest ARS Pharmaceuticals' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of ARS Pharmaceuticals over the last few years. It is ARS Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ARS Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

ARS Operating Cycle Regression Statistics

Arithmetic Mean1,164
Geometric Mean22.15
Coefficient Of Variation275.12
Mean Deviation2,002
Median7.86
Standard Deviation3,203
Sample Variance10.3M
Range9.7K
R-Value0.35
Mean Square Error9.6M
R-Squared0.12
Significance0.17
Slope218.83
Total Sum of Squares164.1M

ARS Operating Cycle History

2026 111.2
2025 117.05
2024 130.05
2022 9672.5
2021 0.0663

About ARS Pharmaceuticals Financial Statements

ARS Pharmaceuticals investors use historical fundamental indicators, such as ARS Pharmaceuticals' Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in ARS Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 117.05  111.20 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for ARS Stock Analysis

When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.